Can Scanfil (HLSE:SCANFL) Stock Sustain Q3 Earnings Strength Amid Cash Strain?

Scanfil Oyj entered Q3 2026 earnings with a slightly tired share price, down over the past week and month, and closing today at €12. The headline result was anything but tired. Revenue reached €252.8m and basic earnings per share came in at €0.18, both solid outcomes for an electronics manufacturing specialist.

The twist lies in the mood, not the math. Recent price softness hints at investor caution just as the business reports strong revenue and net income. That gap between sentiment and fundamentals is the key theme in this report.

Love Scanfil Oyj’s solid Q3 headline numbers but wary of the recent share price softness and sentiment gap? Benchmark this setup against our 192 high quality undervalued stocks.

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): €252.8m vs. €191.3m (up about 32%)
• Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): €11.6m vs. €9.2m (up about 26%)
• Basic EPS (Q3 2026 vs Q3 2025): €0.18 vs. €0.14 (up about 29%)
• Trailing 12-month Net Profit Margin (2026 Q3 vs prior year): 4.8% vs. 4.7% (slightly higher margin)

New project wins and plant expansions now anchor Scanfil’s outlook. Ask Charlie what makes Scanfil confident about its 2027 growth.

Scanfil bullish mission critical mix faces reality check

Optimists argue that Scanfil’s deeper push into regulated, mission critical sectors will steadily reshape earnings quality rather than just add volume.

"Deepening long term customer relationships in regulated and mission critical sectors, shown by rising win plateaus in medtech and life science with quarterly project wins above €10m to €15m and record NPI activity, can improve revenue visibility and support stable earnings as these contracts move from NPI phases into serial production."

Q3 supports this ambition. Aerospace & Defense now contributes about 11% YTD, Medtech & Life Science exceeds €46m YTD, and project wins of €172m underpin backlog. EBITA margin of 7.1% sits close to prior levels, suggesting expansion is not yet lifting profitability but is not diluting it either.

Scanfil cash strain keeps the bear case alive

Sceptics focus on whether this broader, more leveraged platform can actually translate into stronger cash generation, not just higher reported profit.

"Operating cash flow for the first half of 2026 was €5.9m, which reflects pressure from higher receivables and structurally larger working capital needs as the company grows. If cash generation does not improve while reported revenue and earnings continue to rise, investors could discount the quality of those earnings and place a lower value on the share price."

Latest figures show the tension persisting. Q3 operating cash flow of €4.1m trails last year, while working capital has climbed to €254m and net debt to €141m, even with net debt or EBITDA held at 1.5. Earnings are progressing, but balance sheet intensity still weighs on the story.

One Narrative disagrees with today's price. → See where this Narrative says Scanfil Oyj should trade.

Hunt For Quiet Mispricings Now

Scanfil Oyj recently reported strong earnings while its share price response stayed muted. The real opportunity is focusing on stocks that may be undervalued before the market reassesses them.

• Company 1 - 25% below our estimate - taps AI data center optics demand as added manufacturing capacity emphasizes higher value photonics and packaging programs.
• Company 2 - 20% below our estimate - rides a growing data center project backlog while rising receivables and costs in excess of billings reshape its working capital profile.
• Company 3 - 45% below our estimate - integrates a recent banking acquisition to extend its Pacific footprint while aiming to preserve a conservative credit approach and local franchises.

Three companies from the same screener. Open all 192 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com